Synthesis and Characterization of New Palladium(II) Thiosemicarbazone Complexes and Their Cytotoxic Activity against Various Human Tumor Cell Lines

Table 4

IC₅₀ (μm) values^a of the ligands HTSC^1--5, palladium(II) complexes [Pd(TSC^1--5)₂], and cisplatin against the different human tumor cell lines^b.

Human tumor cell lines	H460	DU145	MCF-7	M14	HT-29	K562
HTSC^1	>250	>250	>250	>250	>250	70.86
HTSC^2	>250	31.55	38.05	>250	>250	32.89
HTSC^3	23.48	26.64	34.00	28.67	25.73	35.05
HTSC^4	39.65	26.45	29.94	>250	>250	24.66
HTSC^5	24.95	31.60	25.46	27.31	26.72	27.76
[Pd(TSC^1)2]	9.40	8.27	6.95	9.87	8.20	9.43
[Pd(TSC^2)2]	2.26	2.05	1.61	2.14	1.87	1.95
[Pd(TSC^3)2]	0.23	0.01	0.13	0.05	0.05	0.02
[Pd(TSC^4)2]	2.05	2.39	2.14	2.27	2.37	1.84
[Pd(TSC^5)2]	0.68	0.84	0.78	1.06	1.04	0.65
cisplatin	2.85	6.50	7.20	2.95	7.60	3.20

aIC₅₀ corresponds to the concentration required to inhibit 50% of the cell growth when the cells are exposed to the compounds during 48 h. Each value is the average of two independent experiments.
^bLung large cell carcinoma (H460), prostate carcinoma (DU145), breast adenocarcinoma (MCF-7), amelanotic melanoma (M-14), colon adenocarcinoma (HT-29), and chronic myelogenous leukemia (K562).